.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
Cerilliant
Cipla
US Department of Justice
UBS
Argus Health
Mallinckrodt
Covington
McKinsey
Cantor Fitzgerald

Generated: September 23, 2017

DrugPatentWatch Database Preview

Lamotrigine - Generic Drug Details

« Back to Dashboard

What are the generic sources for lamotrigine and what is the scope of lamotrigine patent protection?

Lamotrigine
is the generic ingredient in five branded drugs marketed by Aurobindo Pharma, Dr Reddys Labs Ltd, Taro, Alembic Pharms Ltd, Sandoz, Zydus Pharms Usa Inc, Pharmascience Inc, Glaxosmithkline Llc, Jubilant Generics, Teva, Mylan, Apotex Inc, Taro Pharm Inds, Watson Labs, Impax Labs Inc, Jubilant Cadista, Actavis Elizabeth, Zydus Pharms Usa, Hikma Pharms, Mylan Labs Ltd, Torrent Pharms, Par Pharm, Actavis Totowa, Glenmark Generics, Torrent Pharms Ltd, Unichem Labs Ltd, Anchen Pharms, Sciegen Pharms Inc, Wockhardt, Cipla Ltd, Handa Pharms Llc, Lupin Ltd, Roxane, Alkem Labs Ltd, Wockhardt Ltd, and Glenmark Pharms Ltd, and is included in forty-nine NDAs. There are five patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Lamotrigine has one hundred and five patent family members in thirty-eight countries.

There are thirty-two drug master file entries for lamotrigine. Sixty-seven suppliers are listed for this compound. There are three tentative approvals for this compound.

Summary for Generic Name: lamotrigine

Tradenames:5
Patents:5
Applicants:36
NDAs:49
Drug Master File Entries: see list32
Suppliers / Packagers: see list67
Bulk Api Vendors: see list75
Clinical Trials: see list175
Patent Applications: see list4,977
Therapeutic Class:Bipolar Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:lamotrigine at DailyMed

Tentative approvals for LAMOTRIGINE

Applicant Application No. Strength Dosage Form
► Subscribe► Subscribe25MGTABLET;ORAL
► Subscribe► Subscribe200MGTABLET;ORAL
► Subscribe► Subscribe150MGTABLET;ORAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmascience Inc
LAMOTRIGINE
lamotrigine
TABLET;ORAL078310-003Feb 4, 2009DISCNNoNo► Subscribe► Subscribe► Subscribe
Actavis Elizabeth
LAMOTRIGINE
lamotrigine
TABLET, EXTENDED RELEASE;ORAL200672-004Oct 17, 2013ABRXNoNo► Subscribe► Subscribe► Subscribe
Lupin Ltd
LAMOTRIGINE
lamotrigine
TABLET;ORAL078691-002Jun 1, 2010ABRXNoNo► Subscribe► Subscribe► Subscribe
Anchen Pharms
LAMOTRIGINE
lamotrigine
TABLET, EXTENDED RELEASE;ORAL201374-006Dec 26, 2012ABRXNoNo► Subscribe► Subscribe► Subscribe
Mylan Labs Ltd
LAMOTRIGINE
lamotrigine
TABLET;ORAL078443-002Feb 11, 2009DISCNNoNo► Subscribe► Subscribe► Subscribe
Mylan
LAMOTRIGINE
lamotrigine
TABLET, CHEWABLE;ORAL076630-002Jan 22, 2009DISCNNoNo► Subscribe► Subscribe► Subscribe
Glaxosmithkline Llc
LAMICTAL ODT
lamotrigine
TABLET, ORALLY DISINTEGRATING;ORAL022251-003May 8, 2009ABRXYesNo► Subscribe► SubscribeYY ► Subscribe
Glaxosmithkline Llc
LAMICTAL ODT
lamotrigine
TABLET, ORALLY DISINTEGRATING;ORAL022251-003May 8, 2009ABRXYesNo► Subscribe► Subscribe► Subscribe
Roxane
LAMOTRIGINE
lamotrigine
TABLET;ORAL077392-003Jan 27, 2009DISCNNoNo► Subscribe► Subscribe► Subscribe
Handa Pharms Llc
LAMOTRIGINE
lamotrigine
TABLET, EXTENDED RELEASE;ORAL202887-001Jun 17, 2013ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: lamotrigine

Non-Orange Book Patents for Generic Ingredient: lamotrigine

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,647,656Orally disintegrating tablet compositions of lamotrigine► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: lamotrigine

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2009006516► Subscribe
Russian Federation2325163► Subscribe
Germany60331041► Subscribe
Eurasian Patent Organization200401071► Subscribe
China100444833► Subscribe
Uruguay31205► Subscribe
EcuadorSP045232► Subscribe
Australia2008272871► Subscribe
United Kingdom0217492► Subscribe
Spain2336319► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
UBS
Daiichi Sankyo
QuintilesIMS
US Department of Justice
Medtronic
McKinsey
Cerilliant
Accenture
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot